Medical Marijuana (OTC: MJNA) reported that its portfolio company AXIM Biotechnologies (OTCQB: AXIM) has been granted a patent by the United States Patent and Trademark Office (USPTO) for a method to treat atopic dermatitis using cannabinoids.
The USPTO has issued a notice of allowance for the patent to the company for a method to treat atopic dermatitis, also known as eczema, using a topical cream containing cannabinoids – specifically cannabidiol (CBD) and cannabigerol (CBG).
AXIM Eyes $5 Billion Atopic Dermatitis Treatment Market
Formulated with cannabinoids, the AXIM’s topical cream will use the company’s combination of CBG and CBD. It is projected to be one of the first CBG products available on the market.
With the patent allowance, AXIM has formulated a topical cream for relief of itching, pain and inflammation that often accompany atopic dermatitis.
“Research has shown evidence that both CBD and CBG provide anti-inflammatory and pain relief benefits,” John Huemoeller, the CEO of AXIM Biotech, said in a statement.
“Our proprietary blend of CBG and CBD is the ideal combination for harnessing these benefits. This product will aim to provide consumers with a topical cream for the $5 billion atopic dermatitis treatment market.”